Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the tolerability of an intravenous infusion of 0.5 and 1.0 mg (actual 0.8 mg)
BIBT 986 BS per hour over 32 hours as well as pharmacokinetics and the effect on blood
coagulation parameters